Share Name Share Symbol Market Type Share ISIN Share Description
Intercytex Group LSE:ICX London Ordinary Share GB00B0762609 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 4.125p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.5 -12.7 - 3.81

Intercytex (ICX) Latest News

Real-Time news about Intercytex (London Stock Exchange): 0 recent articles
More Intercytex News
Intercytex Takeover Rumours

Intercytex (ICX) Share Charts

1 Year Intercytex Chart

1 Year Intercytex Chart

1 Month Intercytex Chart

1 Month Intercytex Chart

Intraday Intercytex Chart

Intraday Intercytex Chart

Intercytex (ICX) Discussions and Chat

Intercytex Forums and Chat

Date Time Title Posts
21/12/201210:42Intercytex - Miracles can happen2,584.00
08/5/200907:50INTERCYTEX (baldness cure) - AIM listed 01.Feb.06 @ 108p311.00

Add a New Thread

Intercytex (ICX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Intercytex trades in real-time

Intercytex (ICX) Top Chat Posts

DateSubject
31/10/2009
18:38
pork belly: Is this the funniest video clip in the history of sharedealing? It is centred around Provexis plc (PXS) a genuine UK AIM listed company run by CEO Stephen Moon. They develop novel functional & medical foods. Their website is: http://www.provexis.com/ They have 3 products: 1. Fruitflow(TM) – which uses tomato extract to 'thin the blood'. This is used in their "Sirco" range of drinks that are sold in the UK. ( http://www.sircoheart.com/index.php/why-should-i-drink-sirco/). 2. NSP#3G - plantain (banana) extract and used for the treatment of inflammatory bowel disease 3. Helicobacter Pylori - currently developing a stabilised extract to treat The share price remained at 0.5p - 1p from Nov 08 all the way to 28 May 09 when they announced that the European Food Safety Authority had accepted a claim that their Fruitflow product did reduce platelet aggregation in humans and that the claim "will go through the final E.U. authorization procedure in the coming weeks." In addition to this they announced "the commencement of a clinical trial for its NSP#3G plantain (banana) medical food for Crohn's disease patients." on 11 Aug 09. As a result of these two RNS's , the shares flew to an intraday high of around 22.75p at the beginning of September as the E.U. approval was expected to be "Transformational" for the company. Many investors were sucked-in at these high prices however, the long awaited "Transformational" E.U. approval still hasn't come and now the shares have moved back to 6p as of 31 Oct 09. Rubbing salt into the wound is the fact that while PSX's share price has collapsed trapping many investors in at high prices, another UK AIM listed company called Gulf Keystone Petroleum (GKP), an oil company, has gone from just 11p to a staggering 105p in the same period, Aug - 31 Oct 09. Now you know the background, watch this videoclip that has recently appeared on Youtube. It is perhaps one of the greatest share related video's ever ! It is the story of one PSX investor who bought into PSX at higher levels awaiting the E.U. approval of Fruitflow. It is a video that almost every investor in the World can relate and, i'm sure, you could replace "PSX" with the "epic" code of one of your stocks. ENJOY !!!!!!!!!!!!!!!! A video diary of a PSX investor: http://www.youtube.com/watch?v=GGsSBv1Cq90
14/10/2009
22:57
grahambr: I think the share price already represents far less than the value of the company. The price was about 12P before the "failed sell off" and had already crashed before that. The products are viable and unique and will attract interest. Its my guess that the company will survive after the selected sell offs with the share price at about double what it is now. This will be a sale at a premium with major share holders satisfied ( best of a bad deal ) IMHO
28/8/2009
04:57
theresearcher: remember we have 4 products a sale of any of them rumoured valveta by an ex-employee @8p would leave a cash rich business with 3 products moving forward.icx-trc has completed phase 11 trials,pfitzer are funding shef so that is of great value on its own,icx-skn our lead product for burns and wounds phase 1 were not conclusive are being looked at in more detail this was the main cause for the share price collapse 47p-------4.75p.8p would only be a stepping stone back too very successfull forward looking business with marketable products ie hair regeneration.it would now appear that the 8p for valveta has come from an ex-employee who would now be reduntant due too the 30 day consultation period.we know they were reducing headcount so this person would now be free too talk.now the main point for a leak massive volume and mm,s holding it back.have a look it all fits interims 18th looks like a few loose ends then we should move north.imho. http://www.intercytex.com/icx/news/releases/2009/2009-07-01/
27/8/2009
20:54
grahambr: there is a good chance that there is something in the air otherwise ICX would have issued the standard statement "we know of no reason why the share price has risen ... " by now.
27/7/2009
16:48
miskers: Hmmm, Saw this start to rise again today but spent much of the afternoon in the cinema watching "Ice Age 3" with the children....great fun... Came back home to see that Omega Fund III, LP and Omega Fund I, LP had reduced their stake to below 3%. Maybe we have just watched a classic case of share price manipulation? 1. Omega go to market makers and say "We have a shed load of ICX to get rid of we are nursing a massive loss after the takeover talks fell through. We want to get rid of a load but it hurts too much to do it at this price 3.75p, can you help?" 2. Market Maker says no problem this is what we do... - Market Maker buys 300,000 plus shares at 3.75p, I and a number of others see this move and think somethings up, buy a few in the hope of averaging down and paring some losses... - A number of others jump on the bandwagon over the next few days and the price gains steadily, Omega begin to off load over 500,000 shares and eventually so do Market Makers. - On the day of the final part of the sting, a number of posters appear and say stuff like, "I heard good things about this share and logged on to see a 40% rise," " I heard the same etc. etc." - Big spike up followed by almost equally big spike down... - RNS about disposal is released... Maybe I have just had another expensive education?
19/6/2009
23:12
robjm66: Offerman the company is for sale so all further trial stages will have to be overcome by who ever buys the company. There was a previous product that was a failure that contributed to the low share price. Even though products have not passed all the phases they have promise some more than others. The company does not have enough funds to bring them to market themselves though so they have no choice but to sell up. The company should have enough funds to last them till they sell up as the projects are largely mothballed and they have laid some staff off in the past. You have missed a lot of the upside with this share but there could be more it all depends on what the various bidders (Pfizer being the biggest) are willing to pay for the different parts of the business. Unlike a lot of posters (largely on three iii) i not going to kid you that have some inside knowledge of what price the company is going to go for or when. Seen lots of guesses from other people they generally range from just under the present share price to the low thirties. You should certainly not have all you money in one stock whatever you do, if you want to get into this one you may have a limited time to make a decision. This is only a quick answer,so of course as usual dyor. Robert
24/5/2009
11:19
robjm66: Very good news to see Pfizer interest confirmed. "THE world's largest drugs producer, Pfizer, is among those interested in making a bid for biotech minnow Intercytex." "By acquiring the company, Pfizer would gain greater control over the whole research process." "However, the US group will not have a clear run as a number of other parties, yet to be named, have also expressed an interest in bidding." Some people are arguing on bulletin boards that everyone new Pfizer were interested in buying the "whole" company and that is reflected in the share price! You have to wonder what planet such people are on. The situation was that as far as the market at large knew Pfizer was just interested in funding in the AMD project. Certainly Pfizer were not falling over themselves to even mention Intercytex and it took a sharp eyed poster to make the connection. Of course we can see now why Pfizer played it the way they did, they hardly wanted to get into any bidding war or pay more than they could get away with. Then we were in the situation that people were worried that Pfizer would fund the AMD project and wait for ICX to go bust or only buy that part of the business from them and ICX would struggle to get any buyers for the business. That is not the situation now and i would rate ICX three main projects on there own as each being worth more than the present market cap and in the AMD case maybe a lot more just on possible royalties. Of course the company may not go for what it really worth in the end but those who are arguing that everything is in the share price are not talking a lot of sense. Robert P.s someone has probably posted this link but just in case. http://www.vavelta.com/
08/5/2009
05:06
incorrigible: see other thread re "almost completely run out of cash" pork belly - 7 May'09 - 22:49 - 304 of 306 Pfizer expanding in Cambridge Written by Lautaro Vargas Thursday, 07 May 2009 http://www.businessweekly.co.uk/2009050734869/life-sciences/pfizer-expanding-in-cambridge.html Pfizer's work on this is also providing a boost for another Cambridge stem cell organisation, Intercytex, whose involvement on the London Project could yield cash royalties. Intercytex has been involved with the London Project to Cure Blindness since its acquisition of Axordia in December 2008 – a collaboration between UCL's Institute of Ophth-almology, Moorfields Eye Hospital, London and the Centre for Stem Cell Biology, Sheffield. In exchange for research funding, and royalties, Axordia is providing UCL with the embryonic stem cell line (SHEF-1) for differentiation into RPE cells. While Intercytex's share price profited from the Pfizer announce-ment with a massive percentage rise, it is thought any payment may come too late. Intercytex has almost completely run out of cash and is now looking for a buyer, having seen its share price plummet over recent months as poor data has seen key products dropped.
07/5/2009
21:49
pork belly: Pfizer expanding in Cambridge Written by Lautaro Vargas Thursday, 07 May 2009 http://www.businessweekly.co.uk/2009050734869/life-sciences/pfizer-expanding-in-cambridge.html Pfizer's work on this is also providing a boost for another Cambridge stem cell organisation, Intercytex, whose involvement on the London Project could yield cash royalties. Intercytex has been involved with the London Project to Cure Blindness since its acquisition of Axordia in December 2008 – a collaboration between UCL's Institute of Ophth-almology, Moorfields Eye Hospital, London and the Centre for Stem Cell Biology, Sheffield. In exchange for research funding, and royalties, Axordia is providing UCL with the embryonic stem cell line (SHEF-1) for differentiation into RPE cells. While Intercytex's share price profited from the Pfizer announce-ment with a massive percentage rise, it is thought any payment may come too late. Intercytex has almost completely run out of cash and is now looking for a buyer, having seen its share price plummet over recent months as poor data has seen key products dropped.
26/4/2009
10:20
waleriuszwatrobka: ...below post from iii bb courtesy of Hub "Pfizer news is a significant life saver for ICX for the following reasons 1. It greatly enhances their chances of getting multiple offers for the company 2. The offer value will be significantly higher than before Pfizer reported involvement. 3. Company does not have to go down the distressed sell option - they will no doubt have significant interest from city on funding through equity placement. 4. Market cap used to be circa 50mln+, currently just 8.5mln and they have 4.5mln in cash. 5. Pfizer are expected to spend circa $100mln on such projects over the next few years and could gain circa 900mln per annum if successful. The carrot is large. 6. It would be sensible for Pfizer to take a significant shareholding in ICX to enable them to have a board member at ICX to help manage relationship and security of the 3 way gang bang between UCL, ICX and Pfizer etc 7. Pfizer have huge Patents booked due for expiry which is going to leave them exposed to commercially to competitors who can replicate their drugs. 8. Pfizer's purchase of wyeth has put huge stress on the board to deliver and the prospect of an 900mln per annum number 1 market product is a delightful foot note to shareholders and I can't see Pfizer allowing that to be tarnished by the potential administration status of one of the key partners and facilitators - ICX 9. The share price has already discounted ICX for failure at the 4p range. It was trading at 40p plus before other unrelated drug failures presented the market with a clear opportunity to mark it down further as prospects looked zero. 10. Prospects are not zero - they are now loaded with zerooooooooooo's in terms of possible revenue - sale suddenly becomes very likely and at a very good price (40p+ minimum) although prospect of funding would appear their number one goal and preferably with Pfizer. Market cap of 8.5mln, should double or treble to reflect the above prospects and even 30mln looks small fry. 11. Majority of shareholders are 'in' at well above 10p and even well above 30p levels - they won't be selling at 10p. The lucky few, moi included currently represent just 10% of the share float, if another 10mln pile in on Monday, then you will have a significant shortage of stock and this could see the share price double on Monday. 12. It's important to remember that although the royalties might be some 3 years away - that part of the news is irrelevant for the time being - it's the very presence of Pfizer's involvement that makes ICX future look solid going forwards. 13. Pfzier would not have gone into the UCL deal without looking at the implications of other involved parties. They will be well aware of ICX and will have already done their due diligence. 14. My conclusion - with so many prospects and the future now very much LESS uncertain, the share price should recovery to more suitable levels that reflects the companies potential and their assets and that price will be determined by buyers and sellers of a small float of circa 90mln shares. HUB nb. this will be in auction for the first 5mins of trading which will make buying early on Monday morning - very tricky indeed. My guess - is that when the mm's 'mates' have had their fill, pi's will be allowed to enter and I can't see that level at anything but 13p+"
Intercytex share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20161204 08:13:05